PAP
AYTU icon

Persistent Asset Partners’s AYTU BioPharma AYTU Stock Holding History

Persistent Asset Partners’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Buy
92,897
+13,482
+17% +$34.5K 0.09% 169
2025
Q4 		$206K Buy
79,415
+16,963
+27% +$38K 0.09% 210
2025
Q3 		$117K Buy
+62,452
New +$144K 0.08% 153

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Persistent Asset Partners's AYTU Position: Q1 2026 in Review

Persistent Asset Partners increased its AYTU BioPharma (AYTU) stake by 17% in Q1 2026, buying an estimated $34.5K and bringing the position to 92,897 shares worth $254K. The position accounts for 0.09% of the portfolio, ranked #169.

Persistent Asset Partners first reported a position in AYTU in Q3 2025 and has held it in 3 quarters since. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Persistent Asset Partners held 92,897 shares of AYTU BioPharma worth $254K as of Q1 2026.
  • Persistent Asset Partners bought 13,482 AYTU BioPharma shares in Q1 2026, an estimated $34.5K.
  • AYTU BioPharma made up 0.09% of Persistent Asset Partners's portfolio in Q1 2026, its #169 holding.
  • Persistent Asset Partners first reported a position in AYTU BioPharma in Q3 2025 and has held it in 3 quarters since.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.